Sublingual Immunotherapy (Grazax®)
A Review of the Cost-Effectiveness of Sublingual Immunotherapy (Grazax®) for the Prevention of Seasonal Grass Pollen-Induced Rhinoconjunctivitis.
Pharmaoeconomic Evaluation
| Commenced | Completed | Outcome |
| September 2007 | Reimbursement not recommended |
The cost-effectiveness of Grazax® remains to be established and this product cannot be recommended as value for money at this point in time.